-
2024-516153-52-00
10
2022-03-28
Macrophage activation syndrome (MAS) in the context of Systemic Juveni
-
2024-510696-38-00
5
2022-03-08
Severe Hypertriglyceridemia.
-
2023-506004-93-00
4
2022-03-01
Ulcerative Colitis (UC)
-
2024-513030-38-00
5
2022-02-15
Invasive fungal infections due to Aspergillus spp.
-
2023-506589-30-00
5
2022-02-09
Invasive Extraintestinal Pathogenic Escherichia coli Disease
-
2024-517846-32-00
5
2021-12-21
Delayed chemotherapy induced nausea and vomiting (CINV)
-
2024-514168-15-00
3
2021-12-17
N+M0 prostate cancer
-
2023-508511-23-00
5
2021-12-02
Amyotrophic Lateral Sclerosis (ALS)
-
2024-510904-36-00
4
2021-10-12
primary Sjögren's Syndrome
-
2023-503813-31-01
5
2021-09-17
Second- or Third-Line Recurrent or Metastatic Cervical Cancer
-
2024-513569-38-00
10
2021-07-09
Crohn's Disease
-
2024-517054-94-00
5
2021-07-05
AMYOTROPHIC LATERAL SCLEROSIS
-
2024-511966-36-00
11
2021-04-26
cervical cancer stage I-IIA
-
2023-508485-15-00
5
2021-04-22
Subjects with documented STEMI, presenting with persistent ischemic ch
-
2023-503291-24-00
9
2021-03-17
Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected
-
2024-513625-23-00
1
2021-03-15
Patients with relapsed or refractory solid tumors, including: Small ce
-
2024-513075-40-00
4
2021-03-01
Relapsed or refractory AL amyloidosis
-
2024-512603-39-00
7
2021-01-08
Haemophilia B
-
2023-508443-40-00
5
2020-12-18
Lung Cancer, Non-Small Cell
-
2024-517575-20-00
4
2020-08-24
different types of brain tumors
-
2023-509732-25-00
7
2020-07-31
metastatic colorectal cancer with a proven
RAS mutation after failure
-
2024-511171-15-00
3
2020-07-06
Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who ha
-
2023-507846-96-00
5
2020-06-19
Type 2 Diabetes Mellitus
-
2023-507669-24-00
5
2019-11-05
Chronic lymphocytic leukemia